RA Capital Management’s Avalo Therapeutics AVTX Stock Holding History

RA Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5M	Buy	1,000,000 +337,032	+51%	+$5.33M	0.16%	65
2026 Q1	$9.9M	Hold	662,968	–	–	0.1%	75
2025 Q4	$12M	Hold	662,968	–	–	0.12%	58
2025 Q3	$8.43M	Sell	662,968 -270,005	-29%	-$2.32M	0.1%	56
2025 Q2	$4.66M	Sell	932,973 -34,027	-4%	-$159K	0.08%	57
2025 Q1	$7.75M	Hold	967,000	–	–	0.13%	68
2024 Q4	$7.18M	Hold	967,000	–	–	0.1%	80
2024 Q3	$9.19M	Buy	+967,000	New	+$9.97M	0.11%	68

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management's AVTX Position: Q2 2026 in Review

RA Capital Management increased its Avalo Therapeutics (AVTX) stake by 51% in Q2 2026, buying an estimated $5.33M and bringing the position to 1,000,000 shares worth $18.5M. The position accounts for 0.16% of the portfolio, ranked #65.

RA Capital Management first reported a position in AVTX in Q3 2024 and has held it in 8 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

RA Capital Management held 1,000,000 shares of Avalo Therapeutics worth $18.5M as of Q2 2026.
RA Capital Management bought 337,032 Avalo Therapeutics shares in Q2 2026, an estimated $5.33M.
Avalo Therapeutics made up 0.16% of RA Capital Management's portfolio in Q2 2026, its #65 holding.
RA Capital Management first reported a position in Avalo Therapeutics in Q3 2024 and has held it in 8 quarters since.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.